OncLive.com(@OncLive):AZUR-1 presented by @AndreaCercek @MSKCancerCenter: dostarlimab x 6 months in locally advanced dMMR/MSI-H #rectalcancer (recently FDA approved): 71% clinical complete response (cCR) rate, 100% durable (2 cCR patients had surgery with path complete response (pCR)), overall 76% had cCR at 12 months or pCR #ESMO26 @myESMO #crcsm

OncLive.com

@OncLive

Healthcare publisher of oncology focused articles, videos, panel discussions, and much more that run the gamut of oncology care and management.

加入 May 2009

2K 正在關注 50.5K 粉絲

OncLive.com@OncLive

2026.10.25 10:31

AZUR-1 presented by @AndreaCercek @MSKCancerCenter: dostarlimab x 6 months in locally advanced dMMR/MSI-H #rectalcancer# (recently FDA approved): 71% clinical complete response (cCR) rate, 100% durable (2 cCR patients had surgery with path complete response (pCR)), overall 76% had cCR at 12 months or pCR #ESMO26# @myESMO #crcsm#